nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Carboplatin—ovarian cancer	0.504	0.636	CbGbCtD
Deferoxamine—XDH—Doxorubicin—ovarian cancer	0.289	0.364	CbGbCtD
Deferoxamine—Injection site reaction—Doxorubicin—ovarian cancer	0.000439	0.00212	CcSEcCtD
Deferoxamine—Cramps of lower extremities—Epirubicin—ovarian cancer	0.000439	0.00212	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000438	0.00211	CcSEcCtD
Deferoxamine—Nervous system disorder—Vinorelbine—ovarian cancer	0.000434	0.0021	CcSEcCtD
Deferoxamine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000434	0.00209	CcSEcCtD
Deferoxamine—Pain—Melphalan—ovarian cancer	0.000434	0.00209	CcSEcCtD
Deferoxamine—Tachycardia—Vinorelbine—ovarian cancer	0.000432	0.00209	CcSEcCtD
Deferoxamine—Skin disorder—Vinorelbine—ovarian cancer	0.00043	0.00208	CcSEcCtD
Deferoxamine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000429	0.00207	CcSEcCtD
Deferoxamine—Bradycardia—Paclitaxel—ovarian cancer	0.000427	0.00206	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Topotecan—ovarian cancer	0.000424	0.00204	CcSEcCtD
Deferoxamine—Neuropathy—Doxorubicin—ovarian cancer	0.000415	0.002	CcSEcCtD
Deferoxamine—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000414	0.002	CcSEcCtD
Deferoxamine—Hypotension—Vinorelbine—ovarian cancer	0.000414	0.002	CcSEcCtD
Deferoxamine—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000412	0.00199	CcSEcCtD
Deferoxamine—Pruritus—Chlorambucil—ovarian cancer	0.000412	0.00199	CcSEcCtD
Deferoxamine—Urticaria—Topotecan—ovarian cancer	0.000411	0.00199	CcSEcCtD
Deferoxamine—Urethral disorder—Paclitaxel—ovarian cancer	0.000411	0.00199	CcSEcCtD
Deferoxamine—Abdominal pain—Topotecan—ovarian cancer	0.000409	0.00198	CcSEcCtD
Deferoxamine—Body temperature increased—Topotecan—ovarian cancer	0.000409	0.00198	CcSEcCtD
Deferoxamine—Cramps of lower extremities—Doxorubicin—ovarian cancer	0.000406	0.00196	CcSEcCtD
Deferoxamine—Visual impairment—Paclitaxel—ovarian cancer	0.000404	0.00195	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000404	0.00195	CcSEcCtD
Deferoxamine—Urticaria—Melphalan—ovarian cancer	0.000403	0.00195	CcSEcCtD
Deferoxamine—Diarrhoea—Chlorambucil—ovarian cancer	0.000398	0.00192	CcSEcCtD
Deferoxamine—Paraesthesia—Vinorelbine—ovarian cancer	0.000398	0.00192	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Epirubicin—ovarian cancer	0.000397	0.00192	CcSEcCtD
Deferoxamine—Infestation—Docetaxel—ovarian cancer	0.000396	0.00191	CcSEcCtD
Deferoxamine—Infestation NOS—Docetaxel—ovarian cancer	0.000396	0.00191	CcSEcCtD
Deferoxamine—Dyspnoea—Vinorelbine—ovarian cancer	0.000395	0.00191	CcSEcCtD
Deferoxamine—Eye disorder—Paclitaxel—ovarian cancer	0.000392	0.00189	CcSEcCtD
Deferoxamine—Tinnitus—Paclitaxel—ovarian cancer	0.000391	0.00189	CcSEcCtD
Deferoxamine—Renal failure—Docetaxel—ovarian cancer	0.000389	0.00188	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000388	0.00187	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000383	0.00185	CcSEcCtD
Deferoxamine—Hypersensitivity—Topotecan—ovarian cancer	0.000382	0.00184	CcSEcCtD
Deferoxamine—Angiopathy—Paclitaxel—ovarian cancer	0.000381	0.00184	CcSEcCtD
Deferoxamine—Pain—Vinorelbine—ovarian cancer	0.000379	0.00183	CcSEcCtD
Deferoxamine—Immune system disorder—Paclitaxel—ovarian cancer	0.000379	0.00183	CcSEcCtD
Deferoxamine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000378	0.00183	CcSEcCtD
Deferoxamine—Renal failure acute—Epirubicin—ovarian cancer	0.000375	0.00181	CcSEcCtD
Deferoxamine—Arrhythmia—Paclitaxel—ovarian cancer	0.000375	0.00181	CcSEcCtD
Deferoxamine—Hypersensitivity—Melphalan—ovarian cancer	0.000374	0.0018	CcSEcCtD
Deferoxamine—Vomiting—Chlorambucil—ovarian cancer	0.00037	0.00179	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.000367	0.00177	CcSEcCtD
Deferoxamine—Pruritus—Topotecan—ovarian cancer	0.000366	0.00177	CcSEcCtD
Deferoxamine—Erythema—Paclitaxel—ovarian cancer	0.000365	0.00176	CcSEcCtD
Deferoxamine—Renal impairment—Epirubicin—ovarian cancer	0.000364	0.00176	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000362	0.00175	CcSEcCtD
Deferoxamine—Pruritus—Melphalan—ovarian cancer	0.000359	0.00173	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.000358	0.00173	CcSEcCtD
Deferoxamine—Diarrhoea—Topotecan—ovarian cancer	0.000354	0.00171	CcSEcCtD
Deferoxamine—Urticaria—Vinorelbine—ovarian cancer	0.000352	0.0017	CcSEcCtD
Deferoxamine—Urinary tract disorder—Docetaxel—ovarian cancer	0.000351	0.0017	CcSEcCtD
Deferoxamine—Muscle spasms—Paclitaxel—ovarian cancer	0.000351	0.0017	CcSEcCtD
Deferoxamine—Body temperature increased—Vinorelbine—ovarian cancer	0.00035	0.00169	CcSEcCtD
Deferoxamine—Abdominal pain—Vinorelbine—ovarian cancer	0.00035	0.00169	CcSEcCtD
Deferoxamine—Connective tissue disorder—Docetaxel—ovarian cancer	0.000349	0.00169	CcSEcCtD
Deferoxamine—Urethral disorder—Docetaxel—ovarian cancer	0.000349	0.00168	CcSEcCtD
Deferoxamine—Renal failure acute—Doxorubicin—ovarian cancer	0.000347	0.00168	CcSEcCtD
Deferoxamine—Diarrhoea—Melphalan—ovarian cancer	0.000347	0.00168	CcSEcCtD
Deferoxamine—Nausea—Chlorambucil—ovarian cancer	0.000346	0.00167	CcSEcCtD
Deferoxamine—Vision blurred—Paclitaxel—ovarian cancer	0.000344	0.00166	CcSEcCtD
Deferoxamine—Visual impairment—Docetaxel—ovarian cancer	0.000343	0.00165	CcSEcCtD
Deferoxamine—Dizziness—Topotecan—ovarian cancer	0.000342	0.00165	CcSEcCtD
Deferoxamine—Renal impairment—Doxorubicin—ovarian cancer	0.000337	0.00163	CcSEcCtD
Deferoxamine—Angioedema—Paclitaxel—ovarian cancer	0.000334	0.00161	CcSEcCtD
Deferoxamine—Eye disorder—Docetaxel—ovarian cancer	0.000332	0.0016	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.000331	0.0016	CcSEcCtD
Deferoxamine—Vomiting—Topotecan—ovarian cancer	0.000329	0.00159	CcSEcCtD
Deferoxamine—Leukopenia—Paclitaxel—ovarian cancer	0.000327	0.00158	CcSEcCtD
Deferoxamine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000326	0.00158	CcSEcCtD
Deferoxamine—Blood creatinine increased—Epirubicin—ovarian cancer	0.000325	0.00157	CcSEcCtD
Deferoxamine—Headache—Topotecan—ovarian cancer	0.000324	0.00157	CcSEcCtD
Deferoxamine—Angiopathy—Docetaxel—ovarian cancer	0.000323	0.00156	CcSEcCtD
Deferoxamine—Vomiting—Melphalan—ovarian cancer	0.000322	0.00156	CcSEcCtD
Deferoxamine—Immune system disorder—Docetaxel—ovarian cancer	0.000321	0.00155	CcSEcCtD
Deferoxamine—Mediastinal disorder—Docetaxel—ovarian cancer	0.00032	0.00155	CcSEcCtD
Deferoxamine—Arrhythmia—Docetaxel—ovarian cancer	0.000318	0.00153	CcSEcCtD
Deferoxamine—Convulsion—Paclitaxel—ovarian cancer	0.000316	0.00153	CcSEcCtD
Deferoxamine—Pruritus—Vinorelbine—ovarian cancer	0.000313	0.00151	CcSEcCtD
Deferoxamine—Myalgia—Paclitaxel—ovarian cancer	0.000311	0.0015	CcSEcCtD
Deferoxamine—Arthralgia—Paclitaxel—ovarian cancer	0.000311	0.0015	CcSEcCtD
Deferoxamine—Erythema—Docetaxel—ovarian cancer	0.000309	0.00149	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000309	0.00149	CcSEcCtD
Deferoxamine—Nausea—Topotecan—ovarian cancer	0.000308	0.00149	CcSEcCtD
Deferoxamine—Diarrhoea—Vinorelbine—ovarian cancer	0.000303	0.00146	CcSEcCtD
Deferoxamine—Nausea—Melphalan—ovarian cancer	0.000301	0.00145	CcSEcCtD
Deferoxamine—Blood creatinine increased—Doxorubicin—ovarian cancer	0.0003	0.00145	CcSEcCtD
Deferoxamine—Asthma—Epirubicin—ovarian cancer	0.0003	0.00145	CcSEcCtD
Deferoxamine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000298	0.00144	CcSEcCtD
Deferoxamine—Oedema—Paclitaxel—ovarian cancer	0.000298	0.00144	CcSEcCtD
Deferoxamine—Muscle spasms—Docetaxel—ovarian cancer	0.000298	0.00144	CcSEcCtD
Deferoxamine—Eosinophilia—Epirubicin—ovarian cancer	0.000297	0.00143	CcSEcCtD
Deferoxamine—Infection—Paclitaxel—ovarian cancer	0.000296	0.00143	CcSEcCtD
Deferoxamine—Shock—Paclitaxel—ovarian cancer	0.000293	0.00142	CcSEcCtD
Deferoxamine—Dizziness—Vinorelbine—ovarian cancer	0.000293	0.00141	CcSEcCtD
Deferoxamine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000292	0.00141	CcSEcCtD
Deferoxamine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000292	0.00141	CcSEcCtD
Deferoxamine—Tachycardia—Paclitaxel—ovarian cancer	0.000291	0.0014	CcSEcCtD
Deferoxamine—Skin disorder—Paclitaxel—ovarian cancer	0.000289	0.0014	CcSEcCtD
Deferoxamine—Vomiting—Vinorelbine—ovarian cancer	0.000282	0.00136	CcSEcCtD
Deferoxamine—Dysuria—Epirubicin—ovarian cancer	0.00028	0.00135	CcSEcCtD
Deferoxamine—Hypotension—Paclitaxel—ovarian cancer	0.000278	0.00134	CcSEcCtD
Deferoxamine—Headache—Vinorelbine—ovarian cancer	0.000278	0.00134	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—ovarian cancer	0.000277	0.00134	CcSEcCtD
Deferoxamine—Leukopenia—Docetaxel—ovarian cancer	0.000277	0.00134	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—ovarian cancer	0.000274	0.00133	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000272	0.00131	CcSEcCtD
Deferoxamine—Convulsion—Docetaxel—ovarian cancer	0.000268	0.00129	CcSEcCtD
Deferoxamine—Paraesthesia—Paclitaxel—ovarian cancer	0.000268	0.00129	CcSEcCtD
Deferoxamine—Infestation NOS—Epirubicin—ovarian cancer	0.000267	0.00129	CcSEcCtD
Deferoxamine—Infestation—Epirubicin—ovarian cancer	0.000267	0.00129	CcSEcCtD
Deferoxamine—Dyspnoea—Paclitaxel—ovarian cancer	0.000266	0.00128	CcSEcCtD
Deferoxamine—Myalgia—Docetaxel—ovarian cancer	0.000263	0.00127	CcSEcCtD
Deferoxamine—Arthralgia—Docetaxel—ovarian cancer	0.000263	0.00127	CcSEcCtD
Deferoxamine—Nausea—Vinorelbine—ovarian cancer	0.000263	0.00127	CcSEcCtD
Deferoxamine—Renal failure—Epirubicin—ovarian cancer	0.000263	0.00127	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000262	0.00126	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000262	0.00126	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—ovarian cancer	0.000259	0.00125	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000257	0.00124	CcSEcCtD
Deferoxamine—Pain—Paclitaxel—ovarian cancer	0.000255	0.00123	CcSEcCtD
Deferoxamine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000253	0.00122	CcSEcCtD
Deferoxamine—Oedema—Docetaxel—ovarian cancer	0.000253	0.00122	CcSEcCtD
Deferoxamine—Infection—Docetaxel—ovarian cancer	0.000251	0.00121	CcSEcCtD
Deferoxamine—Shock—Docetaxel—ovarian cancer	0.000249	0.0012	CcSEcCtD
Deferoxamine—Nervous system disorder—Docetaxel—ovarian cancer	0.000248	0.0012	CcSEcCtD
Deferoxamine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000247	0.00119	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—ovarian cancer	0.000247	0.00119	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—ovarian cancer	0.000247	0.00119	CcSEcCtD
Deferoxamine—Tachycardia—Docetaxel—ovarian cancer	0.000247	0.00119	CcSEcCtD
Deferoxamine—Skin disorder—Docetaxel—ovarian cancer	0.000245	0.00118	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—ovarian cancer	0.000244	0.00118	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000244	0.00118	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—ovarian cancer	0.000243	0.00117	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000242	0.00117	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—ovarian cancer	0.000237	0.00114	CcSEcCtD
Deferoxamine—Urticaria—Paclitaxel—ovarian cancer	0.000237	0.00114	CcSEcCtD
Deferoxamine—Hypotension—Docetaxel—ovarian cancer	0.000236	0.00114	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000236	0.00114	CcSEcCtD
Deferoxamine—Abdominal pain—Paclitaxel—ovarian cancer	0.000236	0.00114	CcSEcCtD
Deferoxamine—Body temperature increased—Paclitaxel—ovarian cancer	0.000236	0.00114	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—ovarian cancer	0.000235	0.00114	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—ovarian cancer	0.000231	0.00112	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00023	0.00111	CcSEcCtD
Deferoxamine—Paraesthesia—Docetaxel—ovarian cancer	0.000227	0.0011	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—ovarian cancer	0.000226	0.00109	CcSEcCtD
Deferoxamine—Dyspnoea—Docetaxel—ovarian cancer	0.000225	0.00109	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—ovarian cancer	0.000224	0.00108	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—ovarian cancer	0.000224	0.00108	CcSEcCtD
Deferoxamine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00022	0.00106	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000219	0.00106	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000218	0.00105	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000218	0.00105	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—ovarian cancer	0.000218	0.00105	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—ovarian cancer	0.000218	0.00105	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—ovarian cancer	0.000217	0.00105	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000216	0.00104	CcSEcCtD
Deferoxamine—Pain—Docetaxel—ovarian cancer	0.000216	0.00104	CcSEcCtD
Deferoxamine—Arrhythmia—Epirubicin—ovarian cancer	0.000214	0.00103	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—ovarian cancer	0.000214	0.00103	CcSEcCtD
Deferoxamine—Pruritus—Paclitaxel—ovarian cancer	0.000211	0.00102	CcSEcCtD
Deferoxamine—Erythema—Epirubicin—ovarian cancer	0.000209	0.00101	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—ovarian cancer	0.000207	0.001	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—ovarian cancer	0.000207	0.000999	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000207	0.000997	CcSEcCtD
Deferoxamine—Diarrhoea—Paclitaxel—ovarian cancer	0.000204	0.000985	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—ovarian cancer	0.000201	0.000972	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—ovarian cancer	0.000201	0.000969	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—ovarian cancer	0.0002	0.000968	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.0002	0.000966	CcSEcCtD
Deferoxamine—Abdominal pain—Docetaxel—ovarian cancer	0.0002	0.000964	CcSEcCtD
Deferoxamine—Body temperature increased—Docetaxel—ovarian cancer	0.0002	0.000964	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—ovarian cancer	0.000198	0.000957	CcSEcCtD
Deferoxamine—Dizziness—Paclitaxel—ovarian cancer	0.000197	0.000952	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—ovarian cancer	0.000197	0.00095	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—ovarian cancer	0.000193	0.000933	CcSEcCtD
Deferoxamine—Vomiting—Paclitaxel—ovarian cancer	0.000189	0.000915	CcSEcCtD
Deferoxamine—Leukopenia—Epirubicin—ovarian cancer	0.000187	0.000902	CcSEcCtD
Deferoxamine—Headache—Paclitaxel—ovarian cancer	0.000187	0.000901	CcSEcCtD
Deferoxamine—Hypersensitivity—Docetaxel—ovarian cancer	0.000186	0.000899	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—ovarian cancer	0.000186	0.000897	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—ovarian cancer	0.000182	0.000879	CcSEcCtD
Deferoxamine—Convulsion—Epirubicin—ovarian cancer	0.000181	0.000873	CcSEcCtD
Deferoxamine—Pruritus—Docetaxel—ovarian cancer	0.000179	0.000863	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—ovarian cancer	0.000178	0.000858	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—ovarian cancer	0.000178	0.000858	CcSEcCtD
Deferoxamine—Nausea—Paclitaxel—ovarian cancer	0.000177	0.000855	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000177	0.000852	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—ovarian cancer	0.000173	0.000835	CcSEcCtD
Deferoxamine—Diarrhoea—Docetaxel—ovarian cancer	0.000173	0.000834	CcSEcCtD
Deferoxamine—Anaphylactic shock—Epirubicin—ovarian cancer	0.00017	0.000823	CcSEcCtD
Deferoxamine—Oedema—Epirubicin—ovarian cancer	0.00017	0.000823	CcSEcCtD
Deferoxamine—Infection—Epirubicin—ovarian cancer	0.000169	0.000817	CcSEcCtD
Deferoxamine—Shock—Epirubicin—ovarian cancer	0.000168	0.000809	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—ovarian cancer	0.000167	0.000808	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—ovarian cancer	0.000167	0.000807	CcSEcCtD
Deferoxamine—Dizziness—Docetaxel—ovarian cancer	0.000167	0.000807	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000167	0.000805	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—ovarian cancer	0.000166	0.000803	CcSEcCtD
Deferoxamine—Skin disorder—Epirubicin—ovarian cancer	0.000165	0.000799	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—ovarian cancer	0.000164	0.000794	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—ovarian cancer	0.000164	0.000794	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000163	0.000789	CcSEcCtD
Deferoxamine—Vomiting—Docetaxel—ovarian cancer	0.000161	0.000775	CcSEcCtD
Deferoxamine—Hypotension—Epirubicin—ovarian cancer	0.000159	0.000769	CcSEcCtD
Deferoxamine—Headache—Docetaxel—ovarian cancer	0.000158	0.000764	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000158	0.000761	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—ovarian cancer	0.000158	0.000761	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—ovarian cancer	0.000157	0.000756	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000155	0.000749	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—ovarian cancer	0.000155	0.000749	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000155	0.000746	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000154	0.000745	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—ovarian cancer	0.000154	0.000743	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—ovarian cancer	0.000153	0.000739	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—ovarian cancer	0.000153	0.000739	CcSEcCtD
Deferoxamine—Dyspnoea—Epirubicin—ovarian cancer	0.000152	0.000733	CcSEcCtD
Deferoxamine—Nausea—Docetaxel—ovarian cancer	0.00015	0.000724	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—ovarian cancer	0.000147	0.000711	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000147	0.00071	CcSEcCtD
Deferoxamine—Pain—Epirubicin—ovarian cancer	0.000146	0.000703	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000144	0.000693	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—ovarian cancer	0.000142	0.000683	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—ovarian cancer	0.000141	0.000679	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000139	0.000673	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000136	0.000657	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—ovarian cancer	0.000135	0.000654	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—ovarian cancer	0.000135	0.000651	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—ovarian cancer	0.000135	0.00065	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—ovarian cancer	0.000135	0.00065	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000129	0.000622	CcSEcCtD
Deferoxamine—Hypersensitivity—Epirubicin—ovarian cancer	0.000126	0.000606	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—ovarian cancer	0.000125	0.000605	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—ovarian cancer	0.000125	0.000602	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—ovarian cancer	0.000125	0.000602	CcSEcCtD
Deferoxamine—Pruritus—Epirubicin—ovarian cancer	0.000121	0.000582	CcSEcCtD
Deferoxamine—Diarrhoea—Epirubicin—ovarian cancer	0.000117	0.000563	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000116	0.000561	CcSEcCtD
Deferoxamine—Dizziness—Epirubicin—ovarian cancer	0.000113	0.000544	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—ovarian cancer	0.000112	0.000539	CcSEcCtD
Deferoxamine—Vomiting—Epirubicin—ovarian cancer	0.000108	0.000523	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—ovarian cancer	0.000108	0.000521	CcSEcCtD
Deferoxamine—Headache—Epirubicin—ovarian cancer	0.000107	0.000515	CcSEcCtD
Deferoxamine—Dizziness—Doxorubicin—ovarian cancer	0.000104	0.000503	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—ovarian cancer	0.000101	0.000489	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—ovarian cancer	0.0001	0.000484	CcSEcCtD
Deferoxamine—Headache—Doxorubicin—ovarian cancer	9.88e-05	0.000477	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—ovarian cancer	9.36e-05	0.000452	CcSEcCtD
